Lundbeck Foundation portfolio company acquired for USD 230m

Vifor Pharma is acquiring biotech company Sanifit, which Lundbeckfonden Ventures has invested in since 2015.

Photo: PR / Vifor Pharma

Biotech company Sanifit is changing hands after Swiss company Vifor Pharma has made a deal to take over the firm.

Vifor Pharma is paying EUR 205m (USD 230m) upfront to acquire the company, while a number of milestone payments could mean an additional EUR 170m (USD 191m) is added to the sales price.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs